8-K current report · filed Nov 4, 2026

Evolus, Inc. (EOLS) 8-K Current Report: November 4, 2026

Item 2.02Item EX-99.1EOLS overview

Short answer

Evolus, Inc. (EOLS) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Evolus announced financial results for the quarter ended September 30, 2026.

Evolus, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Evolus announced financial results for the quarter ended September 30, 2026
  • Detailed results and management commentary are contained in Exhibit 99.1 accompanying the 8-K

Item EX-99.1 · Exhibit EX-99.1

  • Q3 revenue $78.0M, up 13% YoY, led by $70.1M toxin revenue and $7.9M HA gel revenue
  • Adjusted EBITDA $1.2M versus $(3.1)M, marking the fourth consecutive positive quarter despite GAAP operating loss of $8.4M
  • Nine-month Adjusted EBITDA $6.4M versus $(16.5)M, while net loss narrowed to $31.2M from $51.8M
  • Full-year revenue guidance reaffirmed at $330M to $337M, with non-GAAP operating expense guidance reduced to $210M to $213M
  • Cash $41.7M plus approximately $120M non-dilutive capacity, but inventory rose to $82.8M and long-term debt reached $156.9M

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Evolus, Inc. 8-K filings

Get the next EOLS 8-K as it lands

Follow EOLS for push alerts, or ask the research agent what this filing means.